Could Alder Biopharmaceuticals, Inc. (ALDR) Change Direction After Today’s Huge Increase?

December 7, 2017 - By Adrian Erickson

The stock of Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) is a huge mover today! The stock increased 5.29% or $0.55 during the last trading session, reaching $10.95. About 472,741 shares traded. Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) has declined 33.67% since December 7, 2016 and is downtrending. It has underperformed by 50.37% the S&P500.
The move comes after 7 months positive chart setup for the $741.98M company. It was reported on Dec, 7 by Barchart.com. We have $11.39 PT which if reached, will make NASDAQ:ALDR worth $29.68 million more.

Analysts await Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) to report earnings on February, 22. They expect $-1.10 earnings per share, down 13.40 % or $0.13 from last year’s $-0.97 per share. After $-0.92 actual earnings per share reported by Alder Biopharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 19.57 % negative EPS growth.

Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) Ratings Coverage

Among 16 analysts covering Alder Biopharmaceuticals (NASDAQ:ALDR), 14 have Buy rating, 1 Sell and 1 Hold. Therefore 88% are positive. Alder Biopharmaceuticals had 28 analyst reports since August 6, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, June 8 by Needham. The stock has “Outperform” rating by BMO Capital Markets on Wednesday, August 9. The rating was maintained by Credit Suisse with “Outperform” on Tuesday, March 29. On Thursday, June 29 the stock rating was maintained by Aegis Capital with “Buy”. Credit Suisse downgraded it to “Hold” rating and $1700 target in Wednesday, June 28 report. Jefferies maintained the stock with “Buy” rating in Wednesday, July 27 report. The stock of Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) earned “Buy” rating by Jefferies on Wednesday, September 9. As per Monday, July 17, the company rating was maintained by Needham. The firm earned “Buy” rating on Wednesday, November 8 by Needham. Piper Jaffray initiated it with “Overweight” rating and $47 target in Monday, October 31 report.

More news for Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) were recently published by: Fool.com, which released: “Why Alder Biopharmaceuticals Inc Is Sinking Today” on July 12, 2017. Globenewswire.com‘s article titled: “Alder BioPharmaceuticals® to Present at 29th Annual Piper Jaffray Healthcare …” and published on November 22, 2017 is yet another important article.

Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes therapeutic antibodies in the United States, Australia, and Ireland. The company has market cap of $741.98 million. The companyÂ’s lead product candidate includes ALD403, an antibody, which is in Phase II clinical trial to target calcitonin gene-related peptide for the prevention of migraine. It currently has negative earnings. It also develops ALD1910, a genetically engineered monoclonal antibody that is in preclinical study for the treatment of migraine; and Clazakizumab, an antibody, which has been completed Phase IIb clinical trial that inhibits the pro-inflammatory cytokine interleukin-6 for the treatment of rheumatoid and psoriatic arthritis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.